-
Something wrong with this record ?
Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells
B. Aouar, D. Kovarova, S. Letard, A. Font-Haro, J. Florentin, J. Weber, D. Durantel, L. Chaperot, J. Plumas, K. Trejbalova, J. Hejnar, JA. Nunès, D. Olive, P. Dubreuil, I. Hirsch, R. Stranska,
Language English Country United States
Document type Journal Article
NLK
Directory of Open Access Journals
from 2006
Free Medical Journals
from 2006
Public Library of Science (PLoS)
from 2006
PubMed Central
from 2006
Europe PubMed Central
from 2006
ProQuest Central
from 2006-12-01
Open Access Digital Library
from 2006-01-01
Open Access Digital Library
from 2006-10-01
Open Access Digital Library
from 2006-01-01
Medline Complete (EBSCOhost)
from 2008-01-01
Nursing & Allied Health Database (ProQuest)
from 2006-12-01
Health & Medicine (ProQuest)
from 2006-12-01
Public Health Database (ProQuest)
from 2006-12-01
ROAD: Directory of Open Access Scholarly Resources
from 2006
- MeSH
- Cytokines metabolism MeSH
- Dendritic Cells drug effects metabolism MeSH
- Phosphorylation drug effects MeSH
- Protein Kinase Inhibitors pharmacology MeSH
- Syk Kinase antagonists & inhibitors metabolism MeSH
- Humans MeSH
- Immunity, Innate MeSH
- Signal Transduction drug effects physiology MeSH
- Toll-Like Receptors agonists metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Crosslinking of regulatory immunoreceptors (RR), such as BDCA-2 (CD303) or ILT7 (CD85g), of plasmacytoid dendritic cells (pDCs) efficiently suppresses production of type-I interferon (IFN)-α/β and other cytokines in response to Toll-like receptor (TLR) 7/9 ligands. This cytokine-inhibitory pathway is mediated by spleen tyrosine kinase (Syk) associated with the ITAM-containing adapter of RR. Here we demonstrate by pharmacological targeting of Syk that in addition to the negative regulation of TLR7/9 signaling via RR, Syk also positively regulates the TLR7/9 pathway in human pDCs. Novel highly specific Syk inhibitor AB8779 suppressed IFN-α, TNF-α and IL-6 production induced by TLR7/9 agonists in primary pDCs and in the pDC cell line GEN2.2. Triggering of TLR9 or RR signaling induced a differential kinetics of phosphorylation at Y352 and Y525/526 of Syk and a differential sensitivity to AB8779. Consistent with the different roles of Syk in TLR7/9 and RR signaling, a concentration of AB8779 insufficient to block TLR7/9 signaling still released the block of IFN-α production triggered via the RR pathway, including that induced by hepatitis B and C viruses. Thus, pharmacological targeting of Syk partially restored the main pDC function-IFN-α production. Opposing roles of Syk in TLR7/9 and RR pathways may regulate the innate immune response to weaken inflammation reaction.
Centre de Recherche en Cancérologie de Lyon Inserm U1052 CNRS UMR5286 Lyon France
Institute of Molecular Genetics Czech Academy of Sciences Prague Czech Republic
Institute of Organic Chemistry and Biochemistry Czech Academy of Sciences Prague Czech Republic
UJF INSERM U823 University Grenoble Alpes EFS Rhone Alpes Grenoble France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17031690
- 003
- CZ-PrNML
- 005
- 20171025123118.0
- 007
- ta
- 008
- 171025s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1371/journal.pone.0156063 $2 doi
- 035 __
- $a (PubMed)27258042
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Aouar, Besma $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France. $7 gn_A_00007686
- 245 10
- $a Dual Role of the Tyrosine Kinase Syk in Regulation of Toll-Like Receptor Signaling in Plasmacytoid Dendritic Cells / $c B. Aouar, D. Kovarova, S. Letard, A. Font-Haro, J. Florentin, J. Weber, D. Durantel, L. Chaperot, J. Plumas, K. Trejbalova, J. Hejnar, JA. Nunès, D. Olive, P. Dubreuil, I. Hirsch, R. Stranska,
- 520 9_
- $a Crosslinking of regulatory immunoreceptors (RR), such as BDCA-2 (CD303) or ILT7 (CD85g), of plasmacytoid dendritic cells (pDCs) efficiently suppresses production of type-I interferon (IFN)-α/β and other cytokines in response to Toll-like receptor (TLR) 7/9 ligands. This cytokine-inhibitory pathway is mediated by spleen tyrosine kinase (Syk) associated with the ITAM-containing adapter of RR. Here we demonstrate by pharmacological targeting of Syk that in addition to the negative regulation of TLR7/9 signaling via RR, Syk also positively regulates the TLR7/9 pathway in human pDCs. Novel highly specific Syk inhibitor AB8779 suppressed IFN-α, TNF-α and IL-6 production induced by TLR7/9 agonists in primary pDCs and in the pDC cell line GEN2.2. Triggering of TLR9 or RR signaling induced a differential kinetics of phosphorylation at Y352 and Y525/526 of Syk and a differential sensitivity to AB8779. Consistent with the different roles of Syk in TLR7/9 and RR signaling, a concentration of AB8779 insufficient to block TLR7/9 signaling still released the block of IFN-α production triggered via the RR pathway, including that induced by hepatitis B and C viruses. Thus, pharmacological targeting of Syk partially restored the main pDC function-IFN-α production. Opposing roles of Syk in TLR7/9 and RR pathways may regulate the innate immune response to weaken inflammation reaction.
- 650 _2
- $a cytokiny $x metabolismus $7 D016207
- 650 _2
- $a dendritické buňky $x účinky léků $x metabolismus $7 D003713
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a přirozená imunita $7 D007113
- 650 _2
- $a fosforylace $x účinky léků $7 D010766
- 650 _2
- $a inhibitory proteinkinas $x farmakologie $7 D047428
- 650 _2
- $a signální transdukce $x účinky léků $x fyziologie $7 D015398
- 650 _2
- $a kinasa Syk $x antagonisté a inhibitory $x metabolismus $7 D000072377
- 650 _2
- $a toll-like receptory $x agonisté $x metabolismus $7 D051193
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kovarova, Denisa $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France. Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic. Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
- 700 1_
- $a Letard, Sebastien $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France. AB Science, Paris, France.
- 700 1_
- $a Font-Haro, Albert $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic. Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic. Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Florentin, Jonathan $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France.
- 700 1_
- $a Weber, Jan $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Durantel, David $u Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR5286, Lyon, France.
- 700 1_
- $a Chaperot, Laurence $u UJF, INSERM U823, University Grenoble Alpes, EFS Rhone-Alpes, Grenoble, France.
- 700 1_
- $a Plumas, Joel $u UJF, INSERM U823, University Grenoble Alpes, EFS Rhone-Alpes, Grenoble, France.
- 700 1_
- $a Trejbalova, Katerina $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Hejnar, Jiri $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Nunès, Jacques A $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France.
- 700 1_
- $a Olive, Daniel $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France.
- 700 1_
- $a Dubreuil, Patrice $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France.
- 700 1_
- $a Hirsch, Ivan $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France. Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic. Department of Genetics and Microbiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic. Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic.
- 700 1_
- $a Stranska, Ruzena $u Centre de Recherche en Cancérologie de Marseille, Inserm U1068, Marseille, France. CNRS, UMR7258, Marseille, France. Institut Paoli-Calmettes, Marseille, France. Aix-Marseille Université, UM105, Marseille, France.
- 773 0_
- $w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 6 (2016), s. e0156063
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27258042 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20171025123200 $b ABA008
- 999 __
- $a ok $b bmc $g 1255283 $s 992717
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 11 $c 6 $d e0156063 $e 20160603 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
- LZP __
- $a Pubmed-20171025
